Quarterly ResultMay 13, 2026, 04:37 PM
Adicet Bio Q1 Net Loss Narrows to $20.2M; EPS $(1.88)
AI Summary
Adicet Bio reported a reduced net loss of $20.2 million for Q1 2026, an improvement from $28.2 million in Q1 2025, with EPS improving to $(1.88) from $(4.96). This reduction was primarily driven by significant decreases in both research and development and general and administrative expenses. The company maintains sufficient liquidity, with cash, cash equivalents, and short-term investments totaling $137.6 million, expected to fund operations for at least the next twelve months, supported by recent equity offerings.
Key Highlights
- Net loss narrowed to $20.2 million in Q1 2026 from $28.2 million in Q1 2025.
- Net loss per share improved to $(1.88) in Q1 2026 from $(4.96) in Q1 2025.
- Research and development expenses decreased to $17.5 million from $22.8 million year-over-year.
- General and administrative expenses decreased to $4.1 million from $7.1 million year-over-year.
- Total operating expenses fell to $21.6 million in Q1 2026 from $29.9 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $137.6 million as of March 31, 2026.
- Raised $91.7 million net from a January 2024 public offering.
- Raised $74.8 million net from an October 2025 registered direct offering.
Price Impact
More from ACET